联邦制药(03933.HK) 公布,其全资附属公司联邦生物科技自主研发的1类创新药UBT251注射液,已完成在中国2型糖尿病患者中的II期临床研究。UBT251在研究中显示出良好的安全性和耐受性,与其他三激动剂临床试验中观察到的结果基本一致。UBT251注射液在2型糖尿病患者中的II期临床研究达到预期目标,支持其进入下一阶段临床研究。后续公司将尽快启动中国2型糖尿病患者的III期临床研究。(sl/...
Source Link联邦制药(03933.HK) 公布,其全资附属公司联邦生物科技自主研发的1类创新药UBT251注射液,已完成在中国2型糖尿病患者中的II期临床研究。UBT251在研究中显示出良好的安全性和耐受性,与其他三激动剂临床试验中观察到的结果基本一致。UBT251注射液在2型糖尿病患者中的II期临床研究达到预期目标,支持其进入下一阶段临床研究。后续公司将尽快启动中国2型糖尿病患者的III期临床研究。(sl/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.